The molecular basis underlying tumor destruction in vivo by specific antitumor CD8+T cells remains unclear. We propose that the local production of certain tumor necrosis factor (TNF)-family members (death ligands) may be more important for tumor destruction in vivo than previously thought. Also, the apoptotic response of some tumor cells to the TNF-family member TRAIL can be augmented by the proteasome inhibitor bortezomib (Velcade). Thus, bortezomib may sensitize tumor cells to T cell-mediated cytotoxicity and could potentially improve the beneficial effects of immunotherapy. © 2007 Springer Science+Business Media, LLC.
CITATION STYLE
Shanker, A., & Sayers, T. (2007). Sensitizing tumor cells to immune-mediated cytotoxicity. In Advances in Experimental Medicine and Biology (Vol. 601, pp. 163–171). https://doi.org/10.1007/978-0-387-72005-0_17
Mendeley helps you to discover research relevant for your work.